Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128230 · ClinicalTrials.gov registry record · Phase 2
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02128230: Clinical Trial Phase 2 study, sponsored by University of Arkansas.
NCT02128230 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02128230, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Primary Outcome
Toward improving the clinical outcomes of research subjects with high-risk MM (HR-MM) in the context of the immediately preceding TT5 trial 2008-02 and TT3 trials 2003-33 and 2006-66, TT5B will attempt to accelerate and sustain, at 2 years from starting therapy, the proportion of subjects in complete remission (AS-CR-2) by reducing host-imposed toxicity and thus facilitating timely completion of highly synergistic 8-drug combination therapy, including the next generation proteasome inhibitor, Ca
Interventions
- DEVICE myPRS
- DRUG Induction 1 - MEL-10+CFZ-TD-PACE
- DRUG First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
- DRUG Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)
- DRUG Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06-10 |
| Est. Completion | 2019-02-19 |
| Phase | Phase 2 |
Why NCT02128230 stopped before completion
NCT02128230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which myPRS is the first listed.
NCT02128230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02128230 about?
NCT02128230 is a clinical study titled "UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission". The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
What is the current status of trial NCT02128230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-06-10. Estimated completion is 2019-02-19.
What interventions are being tested in trial NCT02128230?
The interventions under investigation include: myPRS (DEVICE), Induction 1 - MEL-10+CFZ-TD-PACE (DRUG), First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) (DRUG), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%) (DRUG), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic) (DRUG).
Who is sponsoring clinical trial NCT02128230?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02128230's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI